Screener
Regeneron Pharmaceuticals REGN Collaboration revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Statements of Operations | ||||
| Revenues: | ||||
| Net product sales | $1,642.4 | $1,631.0 | $3,176.9 | $3,046.6 |
| Collaboration revenue | 2,455.0 | 1,860.7 | 4,354.7 | 3,391.9 |
| Other revenue | 193.3 | 183.9 | 364.5 | 265.8 |
| 4,290.7 | 3,675.6 | 7,896.1 | 6,704.3 | |
| Expenses: | ||||
| Research and development | 1,631.6 | 1,421.7 | 3,175.1 | 2,749.1 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's collaboration revenue — revenue?
- Regeneron Pharmaceuticals (REGN) reported collaboration revenue — revenue of $2.46B in Q2 2026.
- How has Regeneron Pharmaceuticals's collaboration revenue — revenue changed year-over-year?
- Regeneron Pharmaceuticals's collaboration revenue — revenue increased by 31.9% year-over-year, from $1.86B to $2.46B.
- What is the long-term trend for Regeneron Pharmaceuticals's collaboration revenue — revenue?
- Over 3 years (2021 to 2025), Regeneron Pharmaceuticals's collaboration revenue — revenue has grown at a 25.9% compound annual growth rate (CAGR), from $3.67B to $7.33B.
- What does collaboration revenue — revenue mean?
- Collaboration revenue represents income generated through strategic partnerships and joint development agreements with other pharmaceutical or biotechnology entities. This revenue stream typically includes profit-sharing arrangements, milestone payments, and reimbursement for shared research and development costs associated with co-developed therapeutic assets. It reflects the company's ability to leverage external expertise and capital to accelerate drug discovery and commercialization efforts.
Ask your AI about Regeneron Pharmaceuticals's collaboration revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude